CIBC Private Wealth Group
HZNP

CIBC Private Wealth Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

CIBC Private Wealth Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,150
Closed -$19K – 1943
2018
Q2 		$19K Hold
1,150
– – ﹤0.01% 1427
2018
Q1 		$16K Sell
1,150
-3,400
-75% -$50.2K ﹤0.01% 1435
2017
Q4 		$66K Buy
+4,550
New +$63.9K ﹤0.01% 1113

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

CIBC Private Wealth Group's HZNP Position: Q3 2018 in Review

CIBC Private Wealth Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2018, closing a stake of 1,150 shares — an estimated $19K sold.

CIBC Private Wealth Group first reported a position in HZNP in Q4 2017 and held it in 3 quarters. The position peaked at $66K in Q4 2017. 221 funds tracked by Wall St. Rank hold HZNP as of Q3 2018.

  • CIBC Private Wealth Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 1,150 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2018, an estimated $19K.
  • CIBC Private Wealth Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 3 quarters.
  • CIBC Private Wealth Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $66K in Q4 2017.
  • 221 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2018.

Based on CIBC Private Wealth Group's 13F filing for Q3 2018, filed 14 Nov 2018.